US FDA publishes API-salt naming policy

By Gareth Macdonald

- Last updated on GMT

Salt
Salt

Related tags Pharmaceutical drug Fda

Naming drugs using active pharmaceutical ingredients (API) rather than their salts will cut down on medication and dosing errors according to the US Food and Drug Administration (FDA).

Seasoned observers will know the US FDA has been developing its naming policy for API salts – which combine an ionisable drug and a counter-ion– since December 2013 following the implementation of the US Pharmacopoeia's (USP) monograph.

Last week, the regulator published its final guidance​ on the subject, deciding that new drugs will be named after their API alone – ‘newdrug’ and not ‘newdrug hydrochloride’ according to the FDA example – to minimize potential confusion.

The FDA said the policy “should help avoid medication errors that could result from a mismatch of established name and strength​” also suggesting it “will make it easier for healthcare practitioners to calculate an equivalent dose when transferring patients from one dosage form to another​.”

The guidance will apply to all new drugs, although the FDA said it will make exceptions on a case by case basis if the fact the ingredient is a salt is therapeutically important. Approved medicines will not be impacted unless there are specific safety concerns.

Medication errors

According to FDA data, more than 95,000 medication errors have occured in the US since the year 2000​. While it has no solid figures, the agency belives a significant proportion of thses mistakes are related to the drug name.

The FDA takes such concerns into consideration when reviewing the 400 or so drug name and labels submitted by drugmakers each year. The agency rejects around 100 each year for reasons of appropriateness, similar spelling to another currently marketed product, ambiguity in a drug name and/or identifier, or simply beacuse the proposed name is misleading.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars